Answers are grounded in this paper and cite their sources.
Case report shows prucalopride alleviates symptoms in a child with recurrent achalasia, suggesting a potential treatment option.
: Introduction Prucalopride, a prokinetic agent, is beneficial for chronic idiopathic constipation in pediatrics, but its efficacy for upper gastrointestinal motility disorders has not been well explored. Case presentation We present an 11-year old male with type II achalasia who underwent Heller myotomy and Dor fundoplication at age 9 and had recurrence of symptoms one year post-operatively. The patient was evaluated with esophagogastroduodenoscopy (EGD) with biopsy and Functional Luminal Impedance Planimetry Probe (FLIP). Symptoms were determined to be secondary to esophageal dysmotility with ongoing esophagogastrojunction (EGJ) outlet obstruction. The patient had resolution of dysphagia and age-appropriate weight gain after starting prucalopride at 1mg dose, daily, by mouth. His symptoms improved within 30 days after initiation. As of last known follow-up 12 months later, he remained symptom free. We expect to continue the current management indefinitely so long as symptoms remain controlled. Conclusion Prucalopride may be a safe and beneficial escalation of therapy in an attempt to delay or avoid further surgical intervention.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: